Integrated Filing — IndAS



General information about company

Scrip Code 532649
NSE Symbol NECLIFE
MSEI Symbol NOTLISTED
ISIN INE023H01027
Name of company Nectar Lifesciences Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 14-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 06-11-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceutical Business Segment
Start date and time of board meeting 14-11-2026   10:30:00
End date and time of board meeting 14-11-2026   11:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 30-05-2026
Indicate Company website link for updated RPT policy of the Company https://www.neclife.com/about-3-5
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
There is no default by the Company on its loans. The Company has not issued any debt securities.



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 1.10 2.55
Other income 1,702.42 2,330.44
Total income 1,703.52 2,332.99
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 0.00 2.75
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 1.38 0.00
(d) Employee benefit expense 85.86 189.14
(e) Finance costs (0.01) 15.68
(f) Depreciation, depletion and amortisation expense 10.89 21.95
(f) Other Expenses
1 Other Expenses 578.06 3,241.62
Total other expenses 578.06 3,241.62
Total expenses 676.18 3,471.14
3 Total profit before exceptional items and tax 1,027.34 (1,138.15)
4 Exceptional items 0.00 0.00
5 Total profit before tax 1,027.34 (1,138.15)
6 Tax expense
7 Current tax 0.00 0.00
8 Deferred tax 448.89 (370.98)
9 Total tax expenses 448.89 (370.98)
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 578.45 (767.17)
12 Profit (loss) from discontinued operations before tax (129.07) (79.72)
13 Tax expense of discontinued operations (45.11) (27.86)
14 Net profit (loss) from discontinued operation after tax (83.96) (51.86)
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 494.49 (819.03)
17 Other comprehensive income net of taxes 0.00 0.00
18 Total Comprehensive Income for the period 494.49 (819.03)
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 1,942.61 1,942.61
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 0.3 -0.39
Diluted earnings (loss) per share from continuing operations 0.3 -0.39
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations -0.04 -0.03
Diluted earnings (loss) per share from discontinued operations -0.04 -0.03
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 0.26 -0.42
Diluted earnings (loss) per share from continuing and discontinued operations 0.26 -0.42
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes: 1. The above financial results were reviewed by Audit Committee on November 14, 2026, and approved by the Board in its meeting held on November 14, 2026. The statutory auditors of the Company have conducted a “Limited Review” of the above standalone and consolidated unaudited financial results for the quarter and half year ended on September 30, 2026. 2. The Company is exclusively in the pharmaceutical business segment. 3. Previous period’s figures have been regrouped and reclassified wherever necessary to make them comparable with current period. 4. The Statement of Assets and Liability is attached as Annexure 1. 5. The Statement of Cash Flow is attached as Annexure 2. 6. The Company has two wholly owned subsidiaries with the following details: - a) Neclife PT, Unipessoal LDA, remained inoperative during the period. b) Avensis Exports Private Limited (“AEPL”). 7. The Company is Not a Large Corporate as per the framework provided in the SEBI Circular dated October 19, 2023, on Fund raising by issuance of debt securities by Large Entities. 8. Going Concern During the previous financial year, the Company had sold a substantial part of its existing business operations by way of slump sale and incurred losses. The transaction had resulted in significant liquidity, and the Company, after discharging all its debts, continues to possess adequate cash and liquid resources to meet its obligations, if any. Further, the Company had amended its object clause to undertake activities in the real estate sector and is currently evaluating the various projects under the revised business framework. In furtherance of this objective, the Company had also acquired AEPL as its wholly owned subsidiary. Considering the Company’s solvent financial position and availability of funds, the Board believes that the Company will continue to operate as a going concern for the foreseeable future. Accordingly, the financial results have been prepared on a going concern basis. 9. Material Transactions A. Assets Classified as Held for Sale a. Capsule Business (EHGC) The Company had entered into a Business Transfer Agreement (“Capsule BTA”) dated December 20, 2025, with Capnest Health Care Private Limited (“Capnest”) for the slump sale of its Empty Hard Gelatin Capsule business located at Village Bhatoli Kalan, Pargana Dharmpur, Tehsil Baddi, District Solan, Himachal Pradesh (“Capsule Business”), on a going concern basis, for a consideration of Rs.1,990.00 lakhs, including transfer of related receivables and payables/creditors, subject to working capital adjustments specified in the Capsule BTA and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972. The transaction shall be completed in accordance with the terms set out in the Capsule BTA. b. Jammu Unit: Fixed assets pertaining to the Company’s Jammu unit, which has remained inoperative. The same has been disposed of during the period under consideration, and the impact thereof has been disclosed accordingly. c. Other Assets The Company is also evaluating the monetization of the following assets with the objective of optimizing non-core assets and further strengthening its liquidity position: (i) Land near Garhshankar, Punjab: Vacant land situated near Garhshankar, Punjab. A portion of the said land has already been sold in the current quarter, and the balance is expected to be sold by the end of this financial year. Accordingly, the results relating to the above disposed businesses/assets have been disclosed as discontinued operations in accordance with Ind AS 105. Further, in the audited standalone financial results, the net result of “Capsule Business” has been disclosed separately as discontinued operation as required by Indian Accounting Standard (Ind AS) 105 – Asset Held for Sale and Discontinued Operations and Schedule Ill to the Companies Act, 2013. Consequently, the Company's Statement of Profit and Loss for the period ended September 30, 2026, pertains to its continuing operations only and for that purpose the results for the other reporting periods have been restated accordingly. Standalone Operations relating to the “Capsule Business” in respect of total income, total expenses and tax are being disclosed separately as Discontinued operations as part of the results below: Rs. in lakhs S. No. Particulars Quarter Ended Half year ended Year Ended 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 31-Mar-26 Restated Restated Unaudited Unaudited Unaudited Unaudited Unaudited Audited 1 Revenue from 161.03 574.14 9,327.02 735.17 37,393.53 40,138.43 operations 2 Other income 1.62 5.45 2.56 7.07 7.24 1,221.82 3 Total expenses 291.72 530.24 36,428.28 821.96 74,188.43 95,125.77 4 Profit before tax (129.07) 49.35 (27,098.70) (79.72) (36,787.66) (53,765.52) 5 Exceptional item (Gain on slump sale) - - - - - 16,337.32 6 Tax expenses (45.11) 17.25 (9,467.90) (27.86) (12,824.98) (13,873.82) 7 Net profit after tax (83.96) 32.10 (17,630.80) (51.86) (23,962.68) (23,554.38) 10. Pursuant to the approvals granted by the Board, the Company deployed certain surplus funds in mutual fund, ETF and equity instruments during the year. Subsequently, volatility in the financial markets arising from prevailing market conditions and geopolitical developments adversely impacted the value of such investments, resulting in a loss of Rs. 2,672.50 lakhs for the half year ended September 30, 2026 (which includes loss of Rs. 2,513.29 lakhs incurred up to June 30, 2026). The resultant impact has been recognized in the Statement of Profit and Loss in accordance with Ind AS 109 – Financial Instruments.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 350.24
Capital work-in-progress 0.00
Investment property 0.00
Goodwill 0.00
Other intangible assets 0.00
Intangible assets under development 0.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 49.27
Trade receivables, non-current 0.00
Loans, non-current 9,810.00
Other non-current financial assets
1 Other non-current financial assets 23.95
Total of other non-current financial assets 23.95
Total non-current financial assets 9,883.22
Deferred tax assets (net) 22,825.44
Other non-current assets
1 Other non-current assets 55.58
Total of other non-current assets 55.58
Total non-current assets 33,114.48
2 Current assets
Inventories 0.00
Current financial asset
Current investments 5,551.26
Trade receivables, current 0.00
Cash and cash equivalents 11,224.77
Bank balance other than cash and cash equivalents 0.00
Loans, current 708.13
Other current financial assets
Total of other current financial assets 347.95
Total current financial assets 17,832.11
Current tax assets (net)
Other current assets
1 Other current assets 5,957.14
Total of other current assets 5,957.14
Total current assets 23,789.25
3 Non-current assets classified as held for sale 2,758.88
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 59,662.61
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,942.61
Other equity 55,469.15
Total equity attributable to owners of parent 57,411.76
Non controlling interest
Total equity 57,411.76
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
Total of other non-current financial liabilities
Total non-current financial liabilities 0.00
Provisions, non-current 0.49
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 0.49
Current liabilities
Current financial liabilities
Borrowings, current 0.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other current financial liabilities
1 Other current financial liabilities 2,008.71
Total of other current financial liabilities 2,008.71
Total current financial liabilities 2,008.71
Other current liabilities 10.98
1 Other current liabilities 10.98
Total of other current liabilities 10.98
Provisions, current 0.71
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 2,020.40
3 Liabilities directly associated with assets in disposal group classified as held for sale 229.96
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2,250.85
Total equity and liabilites 59,662.61
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax (1,138.15)
Adjustments for reconcile profit (loss)
Adjustments for finance costs 15.83
Adjustments for decrease (increase) in inventories 28.37
Adjustments for decrease (increase) in trade receivables, current 310.50
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 247.10
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (27.41)
Adjustments for other financial assets, current 5,553.06
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 0.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities (14.00)
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 21.95
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (6.47)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current (732.29)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for interest income 689.57
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 1,117.04
Other adjustments to reconcile profit (loss) (79.72)
Other adjustments for non-cash items 0.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) 5,744.39
Net cash flows from (used in) operations 4,606.24
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 4,606.24
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 81,062.65
Other cash payments to acquire equity or debt instruments of other entities 87,989.34
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 2,270.83
Purchase of property, plant and equipment 120.89
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 689.57
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash (91.50)
Net cash flows from (used in) investing activities (4,178.68)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 0.00
Payments of lease liabilities 0.00
Dividends paid 0.00
Interest paid 15.83
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (15.83)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 411.73
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 411.73
Cash and cash equivalents cash flow statement at beginning of period 10,813.04
Cash and cash equivalents cash flow statement at end of period 11,224.77





Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Deepak Jindal & Co. Yes 31-05-2027


Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Nectar Lifesciences Limited Mr. Sanjiv Goyal Chairmand and Managing Director Remuneration Audit Committee approval has been received at the time of appointment/ revision in remuneration. No Special Remarks 111.00 27.38 0.37 Textual Information(1)
2 Nectar Lifesciences Limited Mrs. Raman Goyal Relative of Chairman & Managing Director Purchase of goods or services No 42.00 1.26 1.26
3 Nectar Lifesciences Limited Avensis Exports Private Limited Wholly owned subsidiary Loan No 10.00 9,800.00 9,810.00 Loan 12.00 10 years Unsecured Financial assistance to for its projects and/ or to meet its working capital requirements, operational expenditure, capital expenditure and other legitimate business needs
4 Nectar Lifesciences Limited Avensis Exports Private Limited Wholly owned subsidiary Investment No 0.00 24.96 24.96
5 Nectar Lifesciences Limited Avensis Exports Private Limited Wholly owned subsidiary Interest received No 589.98 60.42 589.98
6 Nectar Lifesciences Limited Mr. Sushil Kapoor Director Any other transaction Amount received towards car policy No 2.22 3.48 5.70
Total value of transaction during the reporting period 755.20



Text Block

Textual Information(1) Audit Committee approval has been received on all prepertual transactions for the term of Managerial Remuneration/ Salary to KMPs/ Sitting Fee/ CSR Expenditure. Further approvals from Board/members have been received as per the Companies Act, 2013